Longitudinal observation of treatment patterns and outcomes for patients with Fibromyalgia: 12-month findings from the REFLECTIONS study

Pain Medicine (United States)

Volumn 14, Issue 9, 2013, Pages 1400-1415

  Robinson, Rebecca L ^a   Kroenke, Kurt ^b   Williams, David A ^c   Mease, Philip ^d,e,f   Chen, Yi ^g   Faries, Douglas ^a   Peng, Xiaomei ^a   Hann, Danette ^g   Wohlreich, Madelaine ^a   Mccarberg, Bill ^h  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d Seattle Rhumatology Associates   (United States)

^e SWEDISH MEDICAL CENTER   (United States)

^f UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^g SYNEOS HEALTH   (United States)

^h KAISER PERMANENTE   (United States)

Author keywords

Fibromyalgia; Longitudinal; Observational; Outcomes; Pharmacotherapy; Treatment

Indexed keywords

AMITRIPTYLINE; BENZODIAZEPINE DERIVATIVE; CHLORIDE; CLOMIPRAMINE; CYCLOBENZAPRINE; DESIPRAMINE; DOSULEPIN; DOXEPIN; DULOXETINE; GABAPENTIN; HYPNOTIC AGENT; IMIPRAMINE; LOFEPRAMINE; MILNACIPRAN; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; OPIATE; PREGABALIN; SEROTONIN UPTAKE INHIBITOR; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE;

ADULT; ARTICLE; BRIEF PAIN INVENTORY; CAREGIVER; CLINICAL FEATURE; CLINICAL PRACTICE; DEMOGRAPHY; DISEASE SEVERITY; ECONOMIC ASPECT; FEMALE; FIBROMYALGIA; FIBROMYALGIA IMPACT QUESTIONNAIRE; HEALTH STATUS; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OUTPATIENT CARE; PATIENT SATISFACTION; SENSITIVITY ANALYSIS; SHEEHAN DISABILITY SCALE; WORK;

FIBROMYALGIA; LONGITUDINAL; OBSERVATIONAL; OUTCOMES; PHARMACOTHERAPY; TREATMENT;

ADULT; ANALGESICS; FEMALE; FIBROMYALGIA; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PATIENT SATISFACTION; PHYSICIAN'S PRACTICE PATTERNS; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84883772612     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/pme.12168     Document Type: Article

References (52)

1. Robinson RL, Jones ML. In search of pharmacoeconomic evaluations for fibromyalgia treatments: A review. Expert Opin Pharmacother 2006;7(8):1027-1039.
2. Wolfe F, Smythe HA, Yunus MB, etal. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: Report of the multicenter criteria committee. Arthritis Rheum 1990;33(2):160-172.
3. Walitt B, Fitzcharles MA, Hassett AL, etal. The longitudinal outcome of fibromyalgia: A study of 1555 patients. J Rheumatol 2011;38(10):2238-2246.
4. Penrod JR, Bernatsky S, Adam V, etal. Health services costs and their determinants in women with fibromyalgia. J Rheumatol 2004;31(7):1391-1398.
5. White LA, Birnbaum HG, Kaltenboeck A, etal. Employees with fibromyalgia: Medical comorbidity, healthcare costs, and work loss. J Occup Environ Med 2008;50(1):13-24.
6. Martinez JE, Ferraz MB, Sato EI, Atra E. Fibromyalgia versus rheumatoid arthritis: A longitudinal comparison of the quality of life. J Rheumatol 1995;22(2):270-274.
7. Finset A, Wigers SH, Götestam KG. Depressed mood impedes pain treatment response in patients with fibromyalgia. J Rheumatol 2004;31(5):976-980.
8. Fitzcharles MA, Costa DD, Pöyhiä R. A study of standard care in fibromyalgia syndrome: A favorable outcome. J Rheumatol 2003;30(1):154-159.
9. Eich W, Hartmann M, Müller A, Fischer H. The role of psychosocial factors in fibromyalgia syndrome. Scand J Rheumatol Suppl 2000;113:30-31.
10. Forseth KO, Husby G, Gran JT, Førre O. Prognostic factors for the development of fibromyalgia in women with self-reported musculoskeletal pain. A prospective study. J Rheumatol 1999;26(11):2458-2467.
11. Felson DT, Goldenberg DL. The natural history of fibromyalgia. Arthritis Rheum 1986;29(12):1522-1526.
12. Ledingham J, Doherty S, Doherty M. Primary fibromyalgia syndrome-An outcome study. Br J Rheumatol 1993;32(2):139-142.
13. Reich JW, Olmsted ME, van Puymbroeck CM. Illness uncertainty, partner caregiver burden and support, and relationship satisfaction in fibromyalgia and osteoarthritis patients. Arthritis Rheum 2006;55(1):86-93.
14. Russell IJ. Fibromyalgia syndrome: Approach to management. Prim Psychiatry 2006;13(9):76-84.
15. Hudson JI, Goldenberg DL, Pope HG Jr, Keck PE Jr, Schlesinger L. Comorbidity of fibromyalgia with medical and psychiatric disorders. Am J Med 1992;92(4):363-367.
16. Bogetto F, Bonatto Revello R, Bertoli C, etal. Fibromyalgia. Psychopathologic aspects. Minerva Psichiatr 1999;40(2):129-138.
17. Cathébras P, Lauwers A, Rousset H. Fibromyalgia. A critical review [article in French]. Ann Med Interne (Paris) 1998;149(7):406-414.
18. Di Franco M, Iannuccelli C, Atzeni F, etal. Pharmacological treatment of fibromyalgia. Clin Exp Rheumatol 2010;28(6 suppl 63):S110-116.
19. Goldenberg DL. Pharmacological treatment of fibromyalgia and other chronic musculoskeletal pain. Best Pract Res Clin Rheumatol 2007;21(3):499-511.
20. Häuser W, Thieme K, Turk DC. Guidelines on the management of fibromyalgia syndrome-A systematic review. Eur J Pain 2010;14(1):5-10.
21. Robinson RL, Birnbaum HG, Morley MA, etal. Economic cost and epidemiological characteristics of patients with fibromyalgia claims. J Rheumatol 2003;30(6):1318-1325.
22. Berger A, Dukes E, Martin S, Edelsberg J, Oster G. Characteristics and healthcare costs of patients with fibromyalgia syndrome. Int J Clin Pract 2007;61(9):1498-1508.
23. White LA, Robinson RL, Yu AP, etal. Comparison of health care use and costs in newly diagnosed and established patients with fibromyalgia. J Pain 2009;10(9):976-983.
24. Harnett J, Margolis J, Cao Z, etal. Real-world evaluation of health-care resource utilization and costs in employees with fibromyalgia treated with pregabalin or duloxetine. Pain Pract 2011;11(3):217-229.
25. Zhao Y, Chen SY, Wu N, Fraser KA, Boulanger L. Medication adherence and healthcare costs among fibromyalgia patients treated with duloxetine. Pain Pract 2011;11(4):381-391.
26. Boulanger L, Wu N, Chen SY, etal. Predictors of pain medication selection among patients diagnosed with fibromyalgia. Pain Pract 2012;12(4):266-275.
27. Bennett RM, Jones J, Turk DC, Russell IJ, Matallana L. An internet survey of 2, 596 people with fibromyalgia. BMC Musculoskelet Disord 2007;8:27.
28. Robinson R, Kroenke K, Mease P, etal. Burden of illness and treatment patterns for patients with fibromyalgia. Pain Med 2012;13(10):1366-1376.
29. Roy-Byrne PP, Sherbourne CD, Craske MG, etal. Moving treatment research from clinical trials to the real world. Psychiatr Serv 2003;54(3):327-332.
30. Mease P, Arnold LM, Bennett R, etal. Fibromyalgia syndrome. J Rheumatol 2007;34(6):1415-1425.
31. Cleeland CS, Ryan KM. Pain assessment: Global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994;23(2):129-138.
32. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol 1996;11(suppl 3):89-95.
33. Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: Development and validation. J Rheumatol 1991;18(5):728-733.
34. Lindquist M. VigiBase, the WHO global ICSR database system: Basic facts. Drug Inf J 2008;42:409-419.
35. Kroenke K, Spitzer RL. Gender differences in the reporting of physical and somatoform symptoms. Psychosom Med 1998;60(2):150-155.
36. O'Malley PG, Jones DL, Feuerstein IM, Taylor AJ. Lack of correlation between psychological factors and subclinical coronary artery disease. N Engl J Med 2000;343(18):1298-1304.
37. Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: The GAD-7. Arch Intern Med 2006;166(10):1092-1097.
38. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: Validity of a brief depression severity measure. J Gen Intern Med 2001;16(9):606-613.
39. Kroenke K, Spitzer R. The PHQ-9: A new depression diagnostic and severity measure. Psychiatr Ann 2002;32:509-521.
40. Bastien CH, Vallières A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med 2001;2(4):297-307.
41. Fava M, Graves LM, Benazzi F, etal. A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. J Clin Psychiatry 2006;67(11):1754-1759.
42. D'Agostino RB Jr, D'Agostino RB Sr. Estimating treatment effects using observational data. JAMA 2007;297(3):314-316.
43. Lunceford J, Davidian M. Stratification and weighting via the propensity score in estimation of causal treatment effects: A comparative study. Stat Med 2004;23(19):2937-2960.
44. Hainmueller J. Entropy balancing for causal effects: A multivariate reweighting method to produce balanced samples in observational studies. Polit Anal 2012;20(1):25-46.
45. Karve S, Cleves MA, Helm M, etal. Prospective validation of eight different adherence measures for use with administrative claims data among patients with schizophrenia. Value Health 2009;12(6):989-995.
46. Karve S, Cleves MA, Helm M, etal. Good and poor adherence: Optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin 2009;25(9):2303-2310.
47. Cramer JA, Roy A, Burrell A, etal. Medication compliance and persistence: Terminology and definitions. Value Health 2008;11(1):44-47.
48. Sewitch MJ, Dobkin PL, Bernatsky S, etal. Medication non-adherence in women with fibromyalgia. Rheumatology (Oxford) 2004;43(5):648-654.
49. Gore M, Sadosky A, Leslie D, Tai KS, Seleznick M. Patterns of therapy switching, augmentation, and discontinuation after initiation of treatment with select medications in patients with osteoarthritis. Clin Ther 2011;33(12):1914-1931.
50. Bieber C, Müller KG, Blumenstiel K, etal. Long-term effects of a shared decision-making intervention on physician-patient interaction and outcome in fibromyalgia: A qualitative and quantitative 1 year follow-up of a randomized controlled trial. Patient Educ Couns 2006;63(3):357-366.
51. Kane RL, Maciejewski M, Finch M. The relationship of patient satisfaction with care and clinical outcomes. Med Care 1997;35(7):714-730.
52. Mease PJ, Dundon K, Sarzi-Puttini P. Pharmacotherapy of fibromyalgia. Best Pract Res Clin Rheumatol 2011;25(2):285-297.